Sunifiram (developmental code name DM-235) is an experimental drug which has antiamnesic effects in animal studies and with significantly higher potency than piracetam.

[3] As of 2016, sunifiram had not been subjected to toxicology testing, nor to any human clinical trials, and is not approved for use anywhere in the world.

[1][3] They specifically did not bind to the glutamate, GABA, serotonin, dopamine, adrenergic, histamine, acetylcholine, or opioid receptors at concentrations of up to 1 μM.

[3] It is reported that sunifiram stimulates CaMKII and PKCα pathways, and that this action depends on the activation of glycine site of NMDA receptors.

[4][5] Sunifiram, as well as other nootropics such as piracetam, levetiracetam, and aniracetam are able to antagonize inhibition of glucose transport by barbiturates (e.g., pentobarbital), diazepam, and certain other drugs in human erythrocytes in vitro (Ki = 26.0 uM for sunifiram), and this action has been found to correlate with their potency in reversing scopolamine-induced memory deficits in mice.